Drug Trial Radar · NCT06372496
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,358
Actual
Start
Apr 16, 2024
Primary completion
Jul 28, 2025
Study completion Jun 14, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
Conditions
- Asthma
Interventions
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatateDrug
Participants will receive FF/UMEC/VI
Inhaled corticosteroids/long-acting beta-2 agonistsDrug
Participants will receive ICS/LABA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24Time frame: Baseline (Day 1) and at Week 24
Locations
117 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Centreville, Alabama
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Newark, Delaware
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
North Miami Beach, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Palm Springs, Florida
GSK Investigational Site
Port Charlotte, Florida
GSK Investigational Site
Tallahassee, Florida
GSK Investigational Site
Normal, Illinois
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Bangor, Maine
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Warren, Michigan
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
Papillion, Nebraska
GSK Investigational Site
Brick, New Jersey
GSK Investigational Site
Linwood, New Jersey
GSK Investigational Site
New Windsor, New York
GSK Investigational Site
Asheville, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Greenville, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
DuBois, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Rock Hill, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Beaumont, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Bellingham, Washington
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.